Truist Financial analyst Srikripa Devarakonda reiterated a Hold rating on Incyte (INCY – Research Report) today. The company’s shares closed yesterday at $68.30. Leverage the power of TipRanks ...

Below is Validea's guru fundamental report for INCYTE CORP (INCY). Of the 22 guru strategies we follow, INCY rates highest using our Multi-Factor Investor model based on the published strategy of ...

I first met Wincy Ong in the buzzing world of advertising and PR, a place where creativity and storytelling intertwine with the art of persuasion. Back then, we were just two professionals navigating ...

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings tomorrow before the bell. Here’s what to expect. Incyte beat analysts’ revenue expectations by 5.2% last ...

Incyte (INCY) reported $1.18 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 16.3%. EPS of $1.43 for the same period compares to $1.06 a year ago.

Greetings, and welcome to the Incyte Fourth Quarter 2024 and Full Year Financial and Corporate Update Conference Call and Webcast. At this time all participants are in listen-only mode. [Operator ...

Incyte (INCY) came out with quarterly earnings of $1.43 per share, missing the Zacks Consensus Estimate of $1.53 per share. This compares to earnings of $1.06 per share a year ago. These figures ...

Shares of Incyte (NASDAQ:INCY) fell 6% Monday after the company released its Q4 earnings report and 2025 sales forecast. The biotech company reported that Q4 revenue rose 16% year-over-year to $1 ...

A number of other brokerages have also recently weighed in on INCY. Oppenheimer raised their target price on shares of Incyte from $81.00 to $82.00 and gave the stock an “outperform” rating in ...